CMG Pharmaceutical Co., Ltd. (058820.KQ)

KRW 1883.0

(-0.79%)

Market Cap (In KRW)

261.53 Billion

Revenue (In KRW)

93.9 Billion

Net Income (In KRW)

6.45 Billion

Avg. Volume

802.32 Thousand

Currency
KRW
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1590.0-2525.0
PE
-
EPS
-
Beta Value
0.671
ISIN
KR7058820002
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Joohyung Lee
Employee Count
-
Website
https://www.cmgpharma.co.kr
Ipo Date
2001-11-19
Details
CMG Pharmaceutical Co., Ltd., a pharmaceutical company, develops and sells oral thin film (OTF) pharmaceuticals in South Korea. It offers Tadalafil OTF products for erectile dysfunction; Entecavir OTF products to treat hepatitis type B; Aripiprazole OTF products for schizophrenia; and Montelukast OTF products to treat asthma and allergic rhinitis. CMG Pharmaceutical Co. Ltd. has a strategic collaboration agreement with Handok Inc. for cancer treatment. The company was formerly known as Skynewpharm Co Ltd and changed its name to CMG Pharmaceutical CO., Ltd. in April 2013. CMG Pharmaceutical Co., Ltd. was founded in 2001 and is headquartered in Seoul, South Korea.